ALB and hepatocellular carcinoma: Prognostic tools such as the model for end-stage liver disease (MELD) score offer excellent performance once significant synthetic failure has occurred but have limitations, which have been well described.[1], [2], [3] Recently, simple scores such as albumin–bilirubin (ALBI), extensively validated in the context of hepatocellular carcinoma (HCC),4 have also been shown to stratify compensated cirrhosis, with no overt synthetic failure, into categorical prognostic groups, but there remains scope to improve upon this.5